Lbp Am Sa Trims Stake in Pfizer Inc. (NYSE:PFE)

LBP AM SA lessened its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 3.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 386,411 shares of the biopharmaceutical company's stock after selling 14,602 shares during the period. LBP AM SA's holdings in Pfizer were worth $9,792,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also made changes to their positions in the company. Providence Capital Advisors LLC raised its holdings in shares of Pfizer by 0.4% during the 4th quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company's stock valued at $3,034,000 after purchasing an additional 409 shares in the last quarter. Donaldson Capital Management LLC grew its stake in shares of Pfizer by 1.2% during the fourth quarter. Donaldson Capital Management LLC now owns 35,694 shares of the biopharmaceutical company's stock valued at $947,000 after purchasing an additional 410 shares during the last quarter. William B. Walkup & Associates Inc. lifted its holdings in Pfizer by 1.2% in the fourth quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company's stock valued at $1,044,000 after buying an additional 454 shares during the period. Sutton Place Investors LLC increased its stake in Pfizer by 5.6% in the first quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company's stock valued at $224,000 after purchasing an additional 472 shares in the last quarter. Finally, Balboa Wealth Partners increased its position in shares of Pfizer by 1.6% during the fourth quarter. Balboa Wealth Partners now owns 30,678 shares of the biopharmaceutical company's stock worth $814,000 after acquiring an additional 480 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Bank of America increased their target price on shares of Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Jefferies Financial Group lifted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research note on Wednesday, May 21st. UBS Group increased their price target on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Cantor Fitzgerald initiated coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price target for the company. Finally, Wolfe Research upped their price target on shares of Pfizer from $22.00 to $23.00 and gave the company an "underperform" rating in a research report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, Pfizer presently has a consensus rating of "Hold" and an average target price of $28.55.

Pfizer Trading Up 0.8%

Shares of NYSE PFE traded up $0.21 during mid-day trading on Thursday, hitting $25.77. The stock had a trading volume of 39,477,537 shares, compared to its average volume of 41,842,555. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The business has a 50 day moving average price of $23.82 and a two-hundred day moving average price of $24.82. The firm has a market cap of $146.49 billion, a P/E ratio of 18.67, a price-to-earnings-growth ratio of 0.93 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The business's revenue for the quarter was down 7.8% compared to the same quarter last year. During the same period in the previous year, the company earned $0.82 earnings per share. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.68%. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.